• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Big Pharma Collaboration Announced with Cocystal and Merck

    Gabrielle Lakusta
    Jan. 03, 2019 03:40PM PST
    Pharmaceutical Investing
    NASDAQ:COCP

    Cocrystal Pharma and Merck have announced a new partnership that ignited investor attention in early trading on Thursday.

    Cocrystal Pharma (NASDAQ:COCP) and Merck (NYSE:MRK) have announced a new partnership that ignited investor attention in early trading on Thursday (January 3).

    The agreement is for an exclusive worldwide license and collaboration agreement for Merck to discover and develop certain proprietary influenza A/B antiviral agents from Cocrystal.

    Cocrystal’s share price was up 19.58 percent early trading on Thursday but settled with a 8.73 percent increase over the one-day trading period to US$4.11 at market close.

    Merck will pay Cocrystal an undisclosed upfront sum and also fund research and development for the program. This includes clinical development and worldwide commercialization of any products derived from the collaboration.

    Cocrystal is eligible to receive payments of up to US$156 million as well as royalties on product sales. These payments consist of designated development, regulatory and sales milestones.

    Dr. Gary Wilcox, vice chairman and CEO of Cocrystal, said in the press release the combination of Merck’s resources and Cocrystal’s innovative platform will enable the company to “advance important new treatments for influenza.”

    The company’s proprietary technology is a structure-based drug discovery strategy for viral replication inhibitors. It’s designed to develop small molecule therapeutics that are safe, effective and convenient to administer.

    The technology offers a 3D structure of inhibitor complexes which guides researchers to a molecule’s novel binding sites. Cocystal has found this also permits the molecules to have a broad spectrum of antiviral activity. As a result, therapies developed may be effective against all sub, or genotypes of a specific virus.

    Cocrystal’s chief scientist was awarded the 2006 Nobel Prize for Chemistry for his work to develop modes of this technology, such as the X-ray crystallography, according to the press release.

    As for Cocrystal’s current pipeline, the company has two influenza programs: one in preclinical development is an influenza A PB2 inhibitor and the other an A/B inhibitor is still in discovery. Approved therapies for these influenza categories are partially effective and prone to viral resistance.

    A and B influenzas are the most predominantly virus types in circulation in the world, according to the World Health Organization. These are mainly recognized as causing seasonal influenza viruses, while others include C and D viruses. During the 2017-2018 flu season, mortality rates sat at 10 percent for both pneumonia and influenza in the US, according to Centers for Disease Control and Prevention (CDC).

    Other drug candidates in Cocrystal’s pipeline includes indications for Hepatitis C and Norovius. One Hep C program is the company’s most advanced drug in development in a Phase 2 trial. As this pipeline exemplifies, the company focuses on antiviral therapeutics based on its proprietary technology.

    Merck is a big pharma known for its global blockbuster drugs in diabetes, cholesterol management and HIV infection among others. More recently, the company’s immuno-oncology drug Keytruda has been widely used in combination trials and collaborations.

    Investors interested in this collaboration can follow both Merck and Cocrystal’s news for updates. Investors can also look forward to hearing about Cocrystal’s PB2 inhibitor which is scheduled to enter a Phase 1 trial in the first half of 2019.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

    pharmaceutical investingcocrystal pharmanasdaq:cocpnyse:mrk
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

    Trading Halt

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—